Vanda Pharma Inc v. Aurobindo Pharma Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Vanda Pharmaceuticals Inc. (Delaware)
  • Defendant: Aurobindo Pharma Limited (India); Aurobindo Pharma U.S.A., Inc. (Delaware); Aurolife Pharma LLC (Delaware)
  • Plaintiff's Counsel: McCarter & English, LLP
• Case Identification: 1:26-cv-00562, D. Del., 05/14/2026
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendants Aurobindo Pharma U.S.A., Inc. and Aurolife Pharma LLC are incorporated in Delaware, and because Defendant Aurobindo Pharma Limited is a foreign defendant that has previously consented to venue in the district.
• Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) for a generic version of the circadian rhythm drug HETLIOZ® (tasimelteon) infringes nine U.S. patents covering methods of treatment and highly purified compositions of the drug.
• Technical Context: The technology relates to the pharmaceutical compound tasimelteon, a melatonin agonist used to treat circadian rhythm disorders such as Non-24-Hour Sleep-Wake Disorder (Non-24), particularly in blind patients.
• Key Procedural History: The lawsuit was initiated under the Hatch-Waxman Act following Vanda's receipt of a notice letter from Aurobindo, which included a Paragraph IV certification alleging that the Orange Book-listed patents for HETLIOZ® are invalid, unenforceable, or will not be infringed by Aurobindo's proposed generic product.

Case Timeline

Date	Event
2012-01-26	Priority Date for '129, '229, '556, '510, and '770 Patents
2014-01-31	Vanda's HETLIOZ® (tasimelteon) NDA No. 205677 approved by FDA
2014-02-12	Priority Date for '977, '011, '740, and '457 Patents
2018-09-11	U.S. Patent No. 10,071,977 Issues
2020-04-07	U.S. Patent No. 10,610,510 Issues
2021-04-20	U.S. Patent No. 10,980,770 Issues
2022-03-29	U.S. Patent No. 11,285,129 Issues
2023-01-31	U.S. Patent No. 11,566,011 Issues
2023-09-19	U.S. Patent No. 11,760,740 Issues
2023-12-26	U.S. Patent No. 11,850,229 Issues
2024-03-05	U.S. Patent No. 11,918,556 Issues
2024-07-30	U.S. Patent No. 12,049,457 Issues
2026-03-31	Vanda receives Aurobindo's ANDA Notice Letter
2026-05-14	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,285,129 - "Treatment of Circadian Rhythm Disorders"

• Patent Identification: U.S. Patent No. 11,285,129, "Treatment of Circadian Rhythm Disorders," issued March 29, 2022.

The Invention Explained

• Problem Addressed: The complaint alleges that prior to the invention, there was no publicly available, scientifically supported information describing the interaction between tasimelteon and beta-adrenergic receptor antagonists, also known as beta blockers Compl. ¶33 Beta blockers have been shown to reduce the body's natural production of melatonin Compl. ¶37
• The Patented Solution: The patent claims methods of administering tasimelteon that account for a newly discovered drug-drug interaction. The invention is premised on the finding that co-administration of beta blockers may reduce the efficacy of tasimelteon '129 Patent, claim 1 Compl. ¶37 The patented method involves determining if a patient is taking beta blockers and, if so, discontinuing their use before starting tasimelteon treatment to improve therapeutic outcomes '129 Patent, claim 1
• Technical Importance: This discovery and method allow for personalized therapeutic regimens by managing a negative drug-drug interaction, thereby potentially improving treatment efficacy for patients with circadian rhythm disorders who are also taking beta blockers Compl. ¶32 Compl. ¶33

Key Claims at a Glance

• The complaint asserts at least claim 1 Compl. ¶79
• Independent claim 1 of the '129 patent recites the following key elements:
  • A method of administering tasimelteon to a patient.
  • The improvement comprising: determining whether the patient is being treated with a beta-adrenergic receptor antagonist.
  • And in the case that the patient is being treated with a beta-adrenergic receptor antagonist, discontinuing that treatment before administering 20 mg of tasimelteon once daily.

U.S. Patent No. 10,610,510 - "Treatment of Circadian Rhythm Disorders"

• Patent Identification: U.S. Patent No. 10,610,510, "Treatment of Circadian Rhythm Disorders," issued April 7, 2020.

The Invention Explained

• Problem Addressed: The complaint alleges that before this invention, there was no scientifically supported public information about the effect of smoking on the administration of tasimelteon Compl. ¶51 The patent notes that smoking induces CYP1A2 enzyme levels, which can alter the metabolism of drugs like tasimelteon '510 Patent, col. 5:15-19
• The Patented Solution: The patent describes the discovery that smoking reduces a patient's exposure to tasimelteon, which may decrease its efficacy '510 Patent, col. 5:15-19 The patent claims methods of administering tasimelteon that account for a patient's smoking status, which include either instructing the patient to cease or reduce smoking before administering a 20 mg dose, or administering a dose greater than 20 mg '510 Patent, claim 1 Figure 12 of the patent shows pharmacokinetic data illustrating the lower concentration of tasimelteon in smokers versus non-smokers '510 Patent, Fig. 12
• Technical Importance: This invention provides a way to personalize treatment for circadian rhythm disorders by accounting for a patient's lifestyle (smoking), which has a significant impact on the drug's metabolism and efficacy '510 Patent, col. 5:15-28

Key Claims at a Glance

• The complaint asserts at least claim 1 Compl. ¶60
• Independent claim 1 of the '510 patent recites the following key elements:
  • A method of administering tasimelteon to a patient.
  • In the case that the patient is a smoker:
    • administering a dose greater than 20 mg once daily; OR
    • instructing the patient to cease or reduce smoking; and administering 20 mg once daily.

Multi-Patent Capsule: Beta Blocker Interaction Patents

• Patent Identification: U.S. Patent Nos. 11,850,229 (issued 12/26/2023) and 11,918,556 (issued 03/05/2024), both titled "Treatment of Circadian Rhythm Disorders."
• Technology Synopsis: These patents, like the '129 patent, relate to methods of administering tasimelteon that account for its interaction with beta blockers Compl. ¶32 They address the problem that beta blockers can reduce tasimelteon's efficacy by providing methods to manage this drug-drug interaction, such as by instructing patients to discontinue beta blocker use before starting tasimelteon Compl. ¶43
• Asserted Claims: At least claim 1 of each patent is asserted Compl. ¶86 Compl. ¶93
• Accused Features: The allegations for these patents are based on Aurobindo's proposed product label, which is expected to be a copy of the HETLIOZ® label and contain warnings about the beta blocker interaction, allegedly inducing infringement Compl. ¶86 Compl. ¶93

Multi-Patent Capsule: Smoker Method of Treatment (MOT) Patent

• Patent Identification: U.S. Patent No. 10,980,770 (issued 04/20/2021), "Treatment of Circadian Rhythm Disorders."
• Technology Synopsis: This patent, like the '510 patent, relates to methods of administering tasimelteon that address its interaction with smoking and also with CYP1A2 inhibitors Compl. ¶50 It is based on the discoveries that smoking can reduce tasimelteon efficacy and that strong CYP1A2 inhibitors can greatly increase tasimelteon exposure Compl. ¶51 Compl. ¶55 Compl. ¶56 The claimed methods involve managing these interactions, for example by instructing patients to cease or reduce smoking or discontinue use of a CYP1A2 inhibitor Compl. ¶61
• Asserted Claims: At least claim 1 is asserted Compl. ¶107
• Accused Features: Infringement allegations are based on Aurobindo's proposed label, which is expected to contain warnings regarding both smoking and CYP1A2 inhibitors, allegedly inducing prescribers to practice the claimed methods Compl. ¶107

Multi-Patent Capsule: High Purity Patents

• Patent Identification: U.S. Patent Nos. 10,071,977 (issued 09/11/2018), 11,566,011 (issued 01/31/2023), 11,760,740 (issued 09/19/2023), and 12,049,457 (issued 07/30/2024), all titled "Highly Purified Pharmaceutical Grade Tasimelteon."
• Technology Synopsis: These patents relate to tasimelteon active pharmaceutical ingredient (API) and pharmaceutical compositions that are highly purified, containing specific low limits of certain named impurities (impurities 1-7) '977 Patent, abstract Compl. ¶70 The patents also cover processes for preparing these high-purity compositions '977 Patent, abstract Compl. ¶70 The technical problem addressed is controlling by-products and degradation products from the synthesis of tasimelteon to ensure a consistent and safe pharmaceutical-grade product '977 Patent, col. 3:1-20
• Asserted Claims: Claim 24 of the '977 patent, claim 4 of the '011 patent, claim 1 of the '740 patent, and claim 1 of the '457 patent are asserted Compl. ¶71
• Accused Features: The complaint alleges on information and belief that Aurobindo's ANDA Product, being bioequivalent to HETLIOZ®, is a pharmaceutical composition that will meet the specific purity limitations of the asserted claims, thereby directly infringing Compl. ¶¶72-76

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Aurobindo's ANDA Product, a proposed generic version of HETLIOZ® (tasimelteon) 20 mg oral capsules, as described in ANDA No. 221356 Compl. p. 1

Functionality and Market Context

The accused product is a generic drug intended for the treatment of Non-24 Compl. ¶24 As an ANDA product, it is represented to the FDA as being bioequivalent to the reference listed drug, HETLIOZ® Compl. ¶25 A critical component of the accused instrumentality is its proposed prescribing information (the "Label"), which under FDA regulations is required to be substantively a copy of the HETLIOZ® label Compl. ¶34 Compl. ¶52 The complaint alleges that this label will contain the same warnings and instructions as the HETLIOZ® label regarding interactions with beta blockers, smoking, and CYP1A2 inhibitors, which form the basis for the indirect infringement allegations Compl. ¶40 Compl. ¶59

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

11,285,129 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of administering tasimelteon to a patient, the improvement comprising: determining whether the patient is being treated with a beta-adrenergic receptor antagonist;	The proposed label for Aurobindo's product allegedly encourages prescribers to determine whether a patient is taking beta blockers before administration, based on warnings about reduced efficacy.	¶43	col. 1:19-25
and in the case that it is determined that the patient is being treated with a beta-adrenergic receptor antagonist, discontinuing beta-adrenergic receptor antagonist treatment before administering to the patient 20 mg of tasimelteon...	The complaint alleges that based on the label's warning that beta blockers "may reduce the efficacy of HETLIOZ," prescribers would be induced to instruct a patient to cease or discontinue using beta blockers prior to administering the product.	¶43; ¶79	col. 2:2-9

10,610,510 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of administering tasimelteon to a patient, the method comprising: in the case that the patient is a smoker: ... instructing the patient to cease or reduce smoking; and administering to the patient 20 mg of tasimelteon once daily before bedtime.	The proposed label for Aurobindo's product allegedly encourages prescribers to determine if a patient is a smoker and, based on warnings that smoking may reduce efficacy, would instruct the patient to cease or reduce smoking prior to administration.	¶61	col. 5:15-19
[The claim includes an alternative step of "administering to the patient a dose of tasimelteon that is greater than 20 mg once daily before bedtime"]	The complaint does not provide sufficient detail for analysis of this alternative step.		col. 5:15-19

Identified Points of Contention

• Scope Questions (Method Patents): A central question for the method claims ('129, '229, '556, '510, '770) will be whether the language on the proposed generic label rises to the level of "instructing" or "encouraging" a prescriber to perform the claimed steps. The defense may argue that the label's text, such as "[n]ighttime administration of beta-adrenergic receptor antagonists may reduce the efficacy of HETLIOZ" Compl. ¶37, is merely a warning of a potential interaction and does not constitute inducement to infringe the claimed methods of discontinuing one drug or instructing a patient to change their smoking habits.
• Technical Questions (Composition Patents): For the High Purity patents ('977, '011, '740, '457), the dispute will be factual and technical. The core question is whether Aurobindo's ANDA product actually meets the claimed impurity limitations (e.g., "no more than about 0.15 %" of specific impurities) Compl. ¶74 This will likely be resolved through competing analytical chemistry data presented by both parties.

V. Key Claim Terms for Construction

For the '129 Patent

• The Term: "discontinuing...treatment"
• Context and Importance: This term is central to the inducement allegation. The case may turn on whether providing information on a product label that one drug "may reduce the efficacy" of another is legally equivalent to an instruction to "discontinue" the first drug, as required by the claim. Practitioners may focus on this term because it is the active step of infringement that Vanda alleges Aurobindo's label will induce doctors to perform.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent does not explicitly define "discontinuing." Vanda may argue that in the context of medical practice, a warning of reduced efficacy serves as an implicit instruction to take steps to avoid that outcome, including discontinuing the interfering drug.
  • Evidence for a Narrower Interpretation: Aurobindo may argue that "discontinuing treatment" requires an affirmative command, which is absent from the label's warning language. The claim recites an active step of "discontinuing," whereas the specification and the HETLIOZ label only describe an observation that efficacy "may be reduced" Compl. ¶37, suggesting a potential mismatch between the claim's requirement and the label's language.

For the '510 Patent

• The Term: "instructing the patient to cease or reduce smoking"
• Context and Importance: Similar to the '129 patent, this term is at the heart of the inducement allegation. The key question is whether the warnings on the label about smoking's negative impact on efficacy constitute an "instruction" to the patient.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: Vanda may argue that the combination of the warning that "efficacy of HETLIOZ may be reduced in smokers" Compl. ¶56 and the "Patient Counseling Information" section Compl. ¶57 implicitly instructs a physician to counsel the patient to stop smoking to achieve the drug's benefit.
  • Evidence for a Narrower Interpretation: Aurobindo may argue that "instructing" requires a direct command from the doctor to the patient, which the label does not explicitly mandate. The '510 patent claims the act of "instructing" but the specification focuses on the discovery of the metabolic effect of smoking, which may support an argument that the claim requires more than merely providing information about that effect '510 Patent, col. 5:15-19

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for the method-of-use patents. Inducement is primarily based on the allegation that Aurobindo's product label will instruct or encourage prescribers and, subsequently, patients to perform the claimed methods (Compl. ¶81; Compl. ¶82). Knowledge and intent are alleged based on Aurobindo's act of seeking FDA approval with a label it knows will lead to infringement Compl. ¶82 Compl. ¶103 Contributory infringement is alleged on the basis that the tasimelteon capsules are a material part of the invention and are not a staple commodity suitable for substantial non-infringing use Compl. ¶83 Compl. ¶104
• Willful Infringement: The complaint does not explicitly plead "willful infringement." However, it requests a declaration that the case is "exceptional" under 35 U.S.C. § 285 and seeks an award of attorney's fees Compl. prayer j The allegations establish that Aurobindo had pre-suit knowledge of the asserted patents via the Paragraph IV notice letter Compl. ¶22

VII. Analyst's Conclusion: Key Questions for the Case

• A primary legal question will be one of inducement: does the language on Aurobindo's proposed label, which warns of reduced efficacy from interactions with beta blockers and smoking, legally constitute an "instruction" or "encouragement" for prescribers to perform the specific steps of discontinuing beta blockers or directing patients to stop smoking, as required by the method claims? Or, do these warnings fall short of the legal standard for inducement?
• A central evidentiary question will be one of chemical composition: does Aurobindo's generic tasimelteon product, in fact, meet the specific, low-level impurity profiles recited in the "High Purity" patents? The resolution of this issue will likely depend on competing chemical analysis and expert testimony regarding the accused product's formulation and manufacturing process.
• The case presents a dual-front dispute characteristic of ANDA litigation: a legal battle over the interpretation and persuasive power of the product label for the method-of-use patents, and a parallel scientific battle over the precise chemical makeup of the drug product for the composition patents.